Journal of Surgical Research
Volume 146, Issue 1 , Pages 16-23, 1 May 2008

Inhibition of In Vivo Tumor Angiogenesis and Growth Via Systemic Delivery of an Angiopoietin 2-Specific RNA Aptamer

  • Shiva Sarraf-Yazdi, M.D.

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, North Carolina
  • ,
  • Jing Mi, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, North Carolina
  • ,
  • Benjamin J. Moeller, M.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
  • ,
  • Xilin Niu, M.D.

      Affiliations

    • Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
  • ,
  • Rebekah R. White, M.D.

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, North Carolina
  • ,
  • Christopher D. Kontos, M.D.

      Affiliations

    • Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina
  • ,
  • Bruce A. Sullenger, Ph.D.

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, North Carolina
  • ,
  • Mark W. Dewhirst, D.V.M., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
  • ,
  • Bryan M. Clary, M.D.

      Affiliations

    • Department of Surgery, Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Surgery, Duke University Medical Center, Box 3247 DUMC, Durham, NC 27710.

Received 10 January 2007 published online 22 October 2007.

Background

Cellular events mediated by the Tie2 receptor are important to tumor neovascularization. Despite the complex interplay of the best-characterized Tie2 ligands, angiopoietins 1 and 2, Ang2 is purportedly “proangiogenic” in the presence of vascular endothelial growth factor. We examined whether in vivo administration of an RNA aptamer that specifically blocks Ang 2 would inhibit tumor angiogenesis and growth.

Methods

Ang2-mediated Tie2 receptor phosphorylation was assessed in vitro in the absence and presence of aptamer coupled to polyethylene glycol.

In vivo angiogenesis assay

CT26 murine colon carcinoma cells expressing green fluorescent protein were delivered into mouse dorsal skinfold window chambers. Animals received daily intraperitoneal injections of phosphate-buffered saline, low-dose (Ang2 aptamer-LD; 1 mg/kg/d), or high-dose aptamer (Ang2 aptamer-HD; 10 mg/kg/d). Vascular length density was measured under fluorescence microscopy.

Primary tumor growth

CT26 cells expressing luciferase were injected into flanks of BALB/c mice to allow tumor growth monitoring by bioluminescence imaging. Animals received continuous phosphate-buffered saline or aptamer (1 mg/kg/d) via ALZET pumps. Tumors were assessed for CD31/PECAM-1 immunostaining and Hoechst dye uptake.

Results

Pegylated aptamer inhibited Tie2 phosphorylation. Systemic aptamer administration reduced vascular length density (P ≤ 0.03) and decreased bioluminescence emission (P < 0.04), corresponding to 50% decrease in tumor volume (P = 0.04). Control tumors displayed abundant vascular marker staining, in contrast to tumors from aptamer-treated animals.

Conclusions

in vivo administration of a clinically relevant, pegylated RNA aptamer specifically designed against Ang2 inhibited tumor angiogenesis and growth. These findings support targeted Ang2 inhibition as a relevant anti-angiogenic, anti-neoplastic strategy.

Key Words: angiopoietin 2, Tie2, angiogenesis, aptamer, dorsal window chamber, bioluminescence imaging

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-4804(07)00319-8

doi:10.1016/j.jss.2007.04.028

Journal of Surgical Research
Volume 146, Issue 1 , Pages 16-23, 1 May 2008